Lexicon Pharmaceuticals has announced that a study published in The Lancet Diabetes & Endocrinology has confirmed the clinical benefits of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor. The findings show that sotagliflozin reduced major adverse cardiovascular events (MACE), heart attack, and stroke among patients with type 2 diabetes, chronic kidney disease, and high cardiovascular risk.
The study, which analyzed data from the SCORED Randomized Trial, found that sotagliflozin had a lower rate of MACE outcomes compared to the placebo group. The medication also showed significant reductions in heart attack and stroke rates. These results suggest that sotagliflozin stands out among other SGLT inhibitors in its ability to reduce cardiovascular risk.
According to Deepak L. Bhatt, MD, the Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine, “Our research team found that sotagliflozin is the only SGLT inhibitor to demonstrate significant reduction of both heart attack and stroke.”
Sotagliflozin has been studied in multiple patient populations and has shown promising results in clinical trials involving approximately 20,000 patients. The medication has the potential to transform patients’ lives by providing innovative treatment options for diseases such as diabetes and chronic kidney disease.
Lexicon Pharmaceuticals is a biopharmaceutical company dedicated to pioneering medicines that transform patients’ lives. With its unique genomics target discovery platform, the company aims to develop innovative treatments for various diseases.
Source: https://finance.yahoo.com/news/published-data-lancet-diabetes-endocrinology-130000325.html